Regenicin Financial Statements From 2010 to 2026
| RGIN Stock | USD 0.0003 0.00 0.00% |
Check Regenicin financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regenicin's main balance sheet or income statement drivers, such as , as well as many indicators such as . Regenicin financial statements analysis is a perfect complement when working with Regenicin Valuation or Volatility modules.
Regenicin |
Regenicin Company Return On Asset Analysis
Regenicin's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Regenicin Return On Asset | -37.38 |
Most of Regenicin's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenicin is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Regenicin has a Return On Asset of -37.3831. This is 327.24% higher than that of the Healthcare sector and 58.4% higher than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
Regenicin Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Regenicin's current stock value. Our valuation model uses many indicators to compare Regenicin value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regenicin competition to find correlations between indicators driving Regenicin's intrinsic value. More Info.Regenicin is rated fourth in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Regenicin by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regenicin's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Regenicin Financial Statements
Regenicin investors utilize fundamental indicators, such as revenue or net income, to predict how Regenicin Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Pair Trading with Regenicin
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regenicin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regenicin will appreciate offsetting losses from the drop in the long position's value.Moving together with Regenicin Pink Sheet
Moving against Regenicin Pink Sheet
| 0.64 | ALNY | Alnylam Pharmaceuticals | PairCorr |
| 0.43 | PBCRF | PT Bank Central Earnings Call This Week | PairCorr |
| 0.41 | ARGX | argenx NV ADR | PairCorr |
| 0.41 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.38 | PBCRY | Bank Central Asia Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Regenicin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regenicin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regenicin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regenicin to buy it.
The correlation of Regenicin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regenicin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regenicin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regenicin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Regenicin Pink Sheet
Regenicin financial ratios help investors to determine whether Regenicin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Regenicin with respect to the benefits of owning Regenicin security.